Down-regulation of ras-related protein rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines

Molecular and Cellular Proteomics

Volumn 13, Issue 11, 2014, Pages 3138-3151

  Jin, Lixu ^b   Huo, Yi ^a   Zheng, Zhiguo ^c   Jiang, Xiaoyong ^a   Deng, Haiyun ^b   Chen, Yuling ^a   Lian, Qingquan ^b   Ge, Renshan ^b   Deng, Haiteng ^a  

^a TSINGHUA UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE 6 PHOSPHATE ISOMERASE; GLUTATHIONE REDUCTASE; HEAT SHOCK PROTEIN 90; LACTATE DEHYDROGENASE; LIPOCORTIN 1; LIPOCORTIN 2; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; PYRUVATE KINASE; RAB 11B PROTEIN; RAB 5C PROTEIN; RAB PROTEIN; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIMENTIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANXA2 PROTEIN, HUMAN; RAB5C PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CELL VIABILITY ASSAY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; DRUG ACCUMULATION; DRUG SENSITIVITY; ENDOCYTOSIS; FLOW CYTOMETRY; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIQUID CHROMATOGRAPHY; NUCLEOTIDE SEQUENCE; OVARIAN CANCER CELL LINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANNEXIN A1; ANNEXIN A2; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; FEMALE; GENE EXPRESSION PROFILING; GLUTATHIONE REDUCTASE; GLYCOLYSIS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; OVARIAN NEOPLASMS; PROTEOMICS; RAB5 GTP-BINDING PROTEINS; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIMENTIN;

EID: 84910635992     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M113.033217     Document Type: Article

References (56)

1. Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Dao, F., Dhir, R., Disaia, P., Gabra, H., and Glenn, P. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615
2. Miller, D. S., Blessing, J. A., Krasner, C. N., Mannel, R. S., Hanjani, P., Pearl, M. L., Waggoner, S. E., and Boardman, C. H. (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinumresistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol. 27, 2686-2691
3. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M. J. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249
4. Fojo, A., Hamilton, T. C., Young, R. C., and Ozols, R. F. (1987) Multidrug resistance in ovarian cancer. Cancer 60, 2075-2080
5. Safaei, R., and Howell, S. B. (2005) Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hemat. 53, 13-23
6. Ishida, S., Lee, J., Thiele, D. J., and Herskowitz, I. (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. 99, 14298-14302
7. Safaei, R., Katano, K., Samimi, G., Naerdemann, W., Stevenson, J. L., Rochdi, M., and Howell, S. B. (2004) Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemoth. Pharm. 53, 239-246
8. Lin, X., Okuda, T., Holzer, A., and Howell, S. B. (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol. 62, 1154-1159
9. Holzer, A. K., Katano, K., Klomp, L. W., and Howell, S. B. (2004) Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 10, 6744-6749
10. Breier, A., Gibalova, L., Seres, M., Barancik, M., and Sulova, Z. (2013) New Insight into P-glycoprotein as a drug target. Anti-Cancer Agent. Me. 13, 159-170
11. Cocker, H. A., Tiffin, N., Pritchard-Jones, K., Pinkerton, C. R., and Kelland, L. R. (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin. Cancer Res. 7, 3193-3198
12. Yang, X., and Page, M. (1995) P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol. Res. 7, 619-624
13. Stordal, B., Hamon, M., McEneaney, V., Roche, S., Gillet, J.-P., O'Leary, J. J., Gottesman, M., and Clynes, M. (2012) Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One 7, e40717
14. Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584
15. Sakamoto, M., Kondo, A., Kawasaki, K., Goto, T., Sakamoto, H., Miyake, K., Koyamatsu, Y., Akiya, T., Iwabuchi, H., and Muroya, T. (2001) Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Human Cell 14, 305-315
16. Li, M., Balch, C., Montgomery, J. S., Jeong, M., Chung, J. H., Yan, P., Huang, T. H., Kim, S., and Nephew, K. P. (2009) Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genomics 2, 34
17. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. 89, 3070-3074
18. Hector, S., Nava, M. E., Clark, K., Murphy, M., and Pendyala, L. (2007) Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Lett. 245, 195-204
19. Martin, L. P., Hamilton, T. C., and Schilder, R. J. (2008) Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 14, 1291-1295
20. Selvakumaran, M., Pisarcik, D. A., Bao, R., Yeung, A. T., and Hamilton, T. C. (2003) Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63, 1311-1316
21. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., and Reed, E. (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94, 703-708
22. Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S. M., Rothenberg, M., Adamo, D. O., Davis, P., and Ognibene, F. P. (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer I. 86, 18-24
23. Murphy, M. A., and Wentzensen, N. (2011) Frequency of mismatch repair deficiency in ovarian cancer: a systematic review. Int. J. Cancer 129, 1914-1922
24. Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., and Couch, F. J. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120
25. Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., and Ashworth, A. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115
26. Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., and Taniguchi, T. (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586
27. Ali, A. Y., Farrand, L., Kim, J. Y., Byun, S., Suh, J. Y., Lee, H. J., and Tsang, B. K. (2012) Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann. NY Acad. Sci. 1271, 58-67
28. Stronach, E. A., Chen, M., Maginn, E. N., Agarwal, R., Mills, G. B., Wasan, H., and Gabra, H. (2011) DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13, 1069-1080
29. Stronach, E. A., Alfraidi, A., Rama, N., Datler, C., Studd, J. B., Agarwal, R., Guney, T. G., Gourley, C., Hennessy, B. T., and Mills, G. B. (2011) HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 71, 4412-4422
30. Yan, X., Pan, L., Yuan, Y., Lang, J., and Mao, N. (2007) Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J. Proteome Res. 6, 772-780
31. Jinawath, N., Vasoontara, C., Jinawath, A., Fang, X., Zhao, K., Yap, K.-L., Guo, T., Lee, C. S., Wang, W., and Balgley, B. M. (2010) Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One 5, e11198
32. Gong, F., Peng, X., Zeng, Z., Yu, M., Zhao, Y., and Tong, A. (2011) Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol. Cell. Biochem. 348, 141-147
33. Di Michele, M., Della Corte, A., Cicchillitti, L., Del Boccio, P., Urbani, A., Ferlini, C., Scambia, G., Donati, M. B., and Rotilio, D. (2009) A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim. Biophys. Acta 1794, 225-236
34. Stewart, J. J., White, J. T., Yan, X., Collins, S., Drescher, C. W., Urban, N. D., Hood, L., and Lin, B. (2006) Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell. Proteomics 5, 433-443
35. Cicchillitti, L., Di Michele, M., Urbani, A., Ferlini, C., Donati, M. B., Scambia, G., and Rotilio, D. (2009) Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J. Proteome Res. 8, 1902-1912
36. Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., and Cullen, K. J. (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 12, 5817-5825
37. Custódio, J., Cardoso, C. M., Santos, M. S., Almeida, L. M., Vicente, J. A., and Fernandes, M. A. (2009) Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology 259, 18-24
38. Saitou, M., Isonishi, S., Hamada, T., Kiyokawa, T., Tachibana, T., Ishikawa, H., and Yasuda, M. (2009) Mitochondrial ultrastructure-Associated chemotherapy response in ovarian cancer. Oncology Reports 21, 199-204
39. Liang, X., Finkel, T., Shen, D., Yin, J., Aszalos, A., and Gottesman, M. M. (2008) SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol. Cancer Res, 6, 1499-1506
40. Andrews, P. A., and Albright, K. D. (1992) Mitochondrial defects in cisdiamminedichloroplatinum (II)-resistant human ovarian carcinoma cells. Cancer Res. 52, 1895-1901
41. Dai, Z., Yin, J., He, H., Li, W., Hou, C., Qian, X., Mao, N., and Pan, L. (2010) Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics 10, 3789-3799
42. Chappell, N. P., Teng, P.-n., Hood, B. L., Wang, G., Darcy, K. M., Hamilton, C. A., Maxwell, G. L., and Conrads, T. P. (2012) Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J. Proteome Res. 11, 4605-4614
43. Minakata, K., Nozawa, H., Okamoto, N., and Suzuki, O. (2006) Determination of platinum derived from cisplatin in human tissues using electrospray ionization mass spectrometry. J. Chromatogr. B 832, 286-291
44. Martinez-Balibrea, E., Plasencia, C., Ginés, A., Martinez-Cardús, A., Musule n, E., Aguilera, R., Manzano, J. L., Neamati, N., and Abad, A. (2009) A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol. Cancer Ther. 8, 771-778
45. Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., and Cantley, L. C. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233
46. Mazurek, S. (2012) Pyruvate kinase M2: a key enzyme of the tumor metabolome and its medical relevance. Biomedical Res. 23, 133-141
47. Xu, R., Pelicano, H., Zhou, Y., Carew, J. S., Feng, L., Bhalla, K. N., Keating, M. J., and Huang, P. (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65, 613-621
48. Chung, Y., Yoo, Y., Park, J., Kim, Y., and Kim, H. J. (2000) Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 21, 1129-1133
49. Pak, J. H., Choi, W. H., Lee, H. M., Joo, W.-D., Kim, J.-H., Kim, Y.-T., Kim, Y.-M., and Nam, J.-H. (2011) Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest. 29, 21-28
50. Satelli, A., and Li, S. (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68, 3033-3046
51. Verrills, N. M., Walsh, B. J., Cobon, G. S., Hains, P. G., and Kavallaris, M. (2003) Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 278, 45082-45093
52. Urbani, A., Poland, J., Bernardini, S., Bellincampi, L., Biroccio, A., Schnölzer, M., Sinha, P., and Federici, G. (2005) A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5, 796-804
53. Kanakkanthara, A., Rawson, P., Northcote, P. T., and Miller, J. H. (2012) Acquired resistance to Peloruside A and laulimalide is associated with down-regulation of vimentin in human ovarian carcinoma cells. Pharm. Res. 29, 3022-3032
54. Arnesano, F., and Natile, G. (2009) Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coordin. Chem. Rev. 253, 2070-2081
55. Shen, D., Su, A., Liang, X., Pai-Panandiker, A., and Gottesman, M. (2004) Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br. J. Cancer 91, 270-276
56. Schwartz, S. L., Cao, C., Pylypenko, O., Rak, A., and Wandinger-Ness, A. (2007) Rab GTPases at a glance. J. Cell Sci. 120, 3905-3910